Original Research

Canadian prescribers’ attitudes and perceptions about ophthalmic biosimilars

Published in: Volume 12 / Year 2023 / Issue 2
Page: 41-9

Author byline as per print journal: Michael S Reilly, Esq; Jane Barratt, PhD Introduction: The first biosimilar entered the Canadian market in 2009 and the first ophthalmic biosimilar was approved… Read More »

Pharmacokinetics and relative bioavailability of sitagliptin hydrochloride and sitagliptin phosphate tablets formulations: a randomized, open-label, crossover study in healthy male volunteers

Published in: Volume 12 / Year 2023 / Issue 1
Page: 12-6

Author byline as per print journal: Chuei Wuei Leong1, PhD; Elton Sagim1, BBiomedSc, Kar Ming Yee1, BPharm; Muhammad Shalhadi Saharuddin1, BSc; Sharifah Radziah Syed Abd Rahim1, MSc; Khairil Sabri1, BSc;… Read More »

Pharmacokinetic bioequivalence of sitagliptin phosphate tablet formulations: a randomized, open-label, crossover study in healthy volunteers

Published in: Volume 12 / Year 2023 / Issue 1
Page: 7-11

Author byline as per print journal: Chuei Wuei Leong1, PhD; Elton Sagim1, BBiomedSc; Kar Ming Yee1, BPharm; Muhammad Shalhadi Saharuddin1, BSc; Nik Mohd Zulhakimi Nik Abdullah1, BSc; Noramirah Farhanah Saberi1,… Read More »

US prescribers’ attitudes and perceptions about biosimilars

Published in: Volume 11 / Year 2022 / Issue 3
Page: 96-103

Author byline as per print journal: Ralph D McKibbin, MD; Michael S Reilly, Esq Introduction: In the United States (US), a legal framework for approving biosimilars was established via the… Read More »

Social trust and regional variation in the adoption of biosimilars in Italy and Germany

Published in: Volume 11 / Year 2022 / Issue 3
Author(s):
Page: 89-95

Introduction/Study Objectives: Adoption of biosimilars has fallen below projections, despite the vigorous implementation of economic incentives, thereby highlighting the importance of behavioural factors such as social trust. This paper analyses… Read More »

A case study of AstraZeneca’s omeprazole/esomeprazole chiral switch strategy

Published in: Volume 11 / Year 2022 / Issue 2
Author(s): ,
Page: 57-64

Author byline as per print journal: Federico J Piñeiro, Pharm, MPH; Fernández Argüelles Rogelio Alberto, Pharm, PhD Introduction/Objective: To describe the chiral switch, an evergreening strategy used by AstraZeneca to position… Read More »

On statistical evaluation for interchangeability of biosimilar products

Published in: Volume 11 / Year 2022 / Issue 2
Page: 51-6

Author byline as per print journal: Yuqi Li, BS Pharm; Shein-Chung Chow, PhD A biosimilar product is a biological product which is highly similar to an existing reference product in structure… Read More »

Extended stability of the trastuzumab biosimilar ABP 980 (KANJINTI™) in polyolefin bags and elastomeric devices

Published in: Volume 10 / Year 2021 / Issue 4
Page: 153-71

Author byline as per print journal: Lyndsay Davies1, PhD; Katie Milligan1, BSc; Mark Corris1, BSc; Ian Clarke1; Paul Dwyer1, MSc; Sarah Elizabeth Lee2, PhD; Jolene Teraoka3, BSc; Jill Crouse-Zeineddini3, PhD; Jane… Read More »

Reasons for patients’ generic drug switching at the pharmacy counter: a pilot study

Published in: Volume 10 / Year 2021 / Issue 3
Page: 119-22

Author byline as per print journal: Pieter J Glerum1,2, MSc; Mert Hayta1,3, PharmD, MSc; David M Burger4, PharmD, PhD; Cees Neef5, PharmD, PhD; Marcel L Bouvy3, PharmD, PhD; Marc Maliepaard1,6,… Read More »

Pharmacokinetics and bioequivalence of generic etoricoxib in healthy volunteers

Published in: Volume 10 / Year 2021 / Issue 3
Page: 113-8

Author byline as per print journal: Nishalini Harikrishnan1, BSc; Ka-Liong Tan2, DPhil; Kar Ming Yee3, BPharm; Alia Shaari Ahmad Shukri1, MSc; Nalla Ramana Reddy4, MBBS; Chuei Wuei Leong3, PhD Introduction/Study… Read More »

Page 1 of 6 1 2 3 4 5 Next »... 6
Go Back Print